Navigation Links
aTyr Pharma Receives Industry Innovation Awards from TiE and San Diego Venture Group
Date:6/18/2012

SAN DIEGO, June 18, 2012 /PRNewswire/ -- aTyr Pharma, an innovative protein therapeutics business, announced today that aTyr has received two industry awards from TiE and San Diego Venture Group (SDVG) for innovation in life sciences.  The awards recognize the advancements aTyr has made in discovering and developing first-in-class opportunities based on Physiocrine biology. Physiocrines represent new protein therapeutic horizons for auto-immune patients.  

The two awards from TiE and SDVG were competitive on a global and a local level, respectively, and sought to identify and recognize the companies that best represented innovation in a range of industries. TiE, a not-for-profit global network of entrepreneurs and professionals, screened more than 2,100 companies from 37 countries to select 50 of the best companies in five areas: mobile, clean tech, software, social networking and life sciences. aTyr won the award in life sciences for the company's innovation, ingenuity, strong management team and quality of ideas. aTyr was also recently recognized as a "Cool Company" by SDVG which selected, from 150 nominees, 30 companies that represented innovation across all industry sectors in San Diego. 

To learn more about aTyr Pharma, Dr. John Mendlein, aTyr's executive chairman and CEO, will be speaking on a panel called, "Beyond Antibodies: Developing Next Generation Biologics" at the upcoming BIO International Convention in Boston, MA.  The panel will take place June 21 from 8:30 am to 9:45 am EDT in Room 253B. 

About Physiocrines
Physiocrines are produced from ancient genes, aminoacyl tRNA synthetases, an intercellular gene family involved in protein synthesis. Overlooked by genomic discovery efforts, Physiocrines are naturally occurring proteins that modulate extracellular signaling pathways in a variety of physiological processes. These endogenous human proteins act through a variety of receptor classes via mechanisms distinct from current pharmaceuticals and have potential applications in a number of therapeutic areas. aTyr is focused on using Physiocrines to generate effective physiologic responses in immune system disorders, including inflammation and disordered immunity.

About aTyr Pharma
aTyr Pharma develops biologic therapeutics based on Physiocrine biology. aTyr has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr's key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures. For more information, please visit http://www.atyrpharma.com.


'/>"/>
SOURCE aTyr Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Big Pharma and Universities Increasingly Work to Advance Life Science Knowledge by Forming Strategic Partnerships, Public-Private Partnerships, and Open Innovation Programs: Pharmaceutical Research Collaborations Summit
2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
3. Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan
4. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
5. Genesis Biopharma Mentioned Favorably in BioMedReports Article
6. Genesis Biopharma Issues Letter To Shareholders
7. New Competitive Arena Emerges for Pharmaceutical Companies in Healthcares Changing Payment Landscape, Finds PwC Health Research Institute Study
8. Questcor Pharmaceuticals Expands Repurchase Program
9. PharmAthene Reports First Quarter 2012 Financial Results
10. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
11. PDL BioPharma to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... , ... May 23, 2017 , ... ... as Vice President of Clinical Operations. She brings years of expertise in ... Therapeutics. From her professional foundation as a licensed occupational therapist, through a variety ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... other leaders of the Maryland Biohealth community in developing and issuing recommendations to ... 3 U.S. BioHealth Innovation Hub by 2023. , The recommendations ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University City Science ... technologies ripe for commercialization, and who are affiliated with the 21 partner academic ... proposals. QED, now in its tenth round, is the first multi-institutional proof-of-concept program ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... psychonneuroendocrine stress expertise, and further enhances its scientific power by providing investigators ... Granger, Ph.D., has agreed to join the scientific advisory board. “We are ...
Breaking Biology Technology:
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):